Susvimo, FDA and Roche
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the leading cause of diabetes-related blindness.
Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...
The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...
Roche, a Swiss pharmaceutical company, anticipates no significant business impact from recent U.S. trade tariffs on Mexico, ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...
Dan Roche offers up a plan for the Red Sox to go out and sign Alex Bregman, which he believes would solidify Boston as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback